Abbott signs agreement to market 24 Zydus Cadila products

US-based drug maker Abbott has announced a licensing and supply agreement to sell 24 with Zydus Cadila drugs in 15 emerging markets in a bid to accelerate its emerging markets growth.

However, the financial terms of the agreement were not disclosed nor the products that Abbott will market for Zydus.

Under the agreement, Abbott will gain marketing rights for the  Zydus products in high-growth emerging where Abbott says it has a strong and growing presence.

According to Abbott, the agreement also includes an option for the addition of more than 40 Zydus products to the collaboration.

"Branded generics represent the most significant growth opportunity in emerging markets," said Abbott.

Product launches under the collaboration are expected to begin in early 2012, it added.